Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial

Clinical Trials

Click here to
learn more.

SciStar Study - Asterias Bio
Asterias is conducting a clinical study to evaluate the safety and activity of AST-OPC1 in patients with cervical spinal cord injury. AST-OPC1 consists of cells known as oligodendrocyte progenitor cells (OPCs). The purpose of the study is to evaluate the safety of AST-OPC1 administered once between 21 & 42 days after injury. Researchers will also assess the impact on patient hand & arm function.


Stock Quote
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.

Asterias Biotherapeutics Tel: (510) 456-3800